• 1
    Levi M, Ten Cate H, Van der Poll T, et al. Pathogenesis of disseminated intravascular coagulation in sepsis. J Am Med Assoc 1993;270:975979.
  • 2
    Mavrommatis AC, Theodoridism T, Orfanidou A, et al. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med 2000;28:451457.
  • 3
    Esmon CT, Fukudome K, Mather T, et al. Inflammation, sepsis, and coagulation. Heamatol 1999;84:254259.
  • 4
    Gando S, Nanzaki S, Sasaki S, et al. Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med 1998;26:20052009.
  • 5
    Esmon CT, Taylor FB, Snow TR. Inflammation and coagulation: Linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991;66:160165.
  • 6
    Thijs LG, De Boer JP, De Groot M, et al. Coagulation disorders in septic shock. Intens Care Med 1993;19 (Suppl 1):S1S15.
  • 7
    Hesselvik JF, Malm J, Dahlback B. Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 1991;65:126129.
  • 8
    Yan SB, Helterbrand JD, Hartman DL, et al. Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001;120:915922.
  • 9
    Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation: Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816823.
  • 10
    Philippe J, Offner F, Declerck PJ, et al. Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost 1991;65:291295.
  • 11
    Lorente JA, Gardia-Frade LJ, Landin L, et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993;103:15361542.
  • 12
    Otto CM, Rieser TM, Brooks MB, et al. Evidence of hypercoagulability in dogs with parvoviral enteritis. J Am Vet Med Assoc 2000;217:15001504.
  • 13
    De Laforcade AM, Freeman LM, Shaw SP, et al. Hemostatic changes in dogs with naturally occurring sepsis. J Vet Intern Med 2003;17:674679.
  • 14
    LaRue MJ, Murtaugh RJ. Pulmonary thromboembolism in dogs: 47 cases (1986–1987). J Am Vet Med Assoc 1990;197:13681372.
  • 15
    Hauptman JG, Walshaw R, Olivier NB. Evaluation of the sensitivity and specificity of diagnostic criteria for sepsis in dogs. Vet Surg 1997;26:393397.
  • 16
    Maddala GS. Limited-Dependent and Qualititative Variables in Econometrics. Cambridge, UK: Cambridge University Press; 1983:221256.
  • 17
    Greene W. Econometric Analysis, 4th ed. Upper Saddle River, NJ: Prentice Hall; 2000:896938.
  • 18
    Leigh JP, Ward MM, Fries JF. Reducing attrition bias with an instrumental variable in a regression model: Results from a panel of rheumatoid arthritis patients. Stat Med 1993;12:10051018.
  • 19
    Palmer KG, King LG, Van Winkle TJ. Clinical manifestations and associated disease syndromes in dogs with cranial vena cava thrombosis. J Am Vet Med Assoc 1998;213:220224.
  • 20
    Johnson LR, Lappin Mr, Baker DC. Pulmonary thromboembolism in 29 dogs (1985–1995). J Vet Intern Med 1999;13:338345.
  • 21
    Norris CR, Griffey SM, Samii VF. Pulmonary thromboembolism in cats: 29 cases (1987–1997). J Am Vet Med Assoc 1999;215:16501654.
  • 22
    Tanaka T, Tsujinaka T, Kambayashi J, et al. The effect of heparin on multiple organ failure and disseminated intravascular coagulation in a sepsis model. Thromb Res 1990;60:321330.
  • 23
    Jaimes F, De La Rosa G, Arango C. A randomized clinical trial of unfractionated heparin for treatment of sepsis (the HETRASE study): Design and rationale. Trials 2006;7:19.
  • 24
    Marlar RA, Endres-Brooks J, Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood 1985;66:5963.
  • 25
    Dickneite G, Leithauser B. Influence of antithrombin III on coagulation and inflammation in porcine septic shock. 1999;19:15661572.
  • 26
    Yamauchi T, Umeda F, Inoguchi T, et al. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 1989;163:14041411.
  • 27
    Uchiba M, Okajima K. Antithrombin III (ATIII) prevents LPS-induced vascular injury: Novel biological activity of AT III. Semin Thromb Hemost 1997;23:583590.
  • 28
    Ostrovsky L, Woodman R, Payne D, et al. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997;96:23022310.
  • 29
    Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Sem Thromb Hemost 2006;32 (Suppl 1):4960.
  • 30
    Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: Integrated to regulate coagulation and inflammation. Arterioscler Thromb Vasc Biol 2004;24:13741383.
  • 31
    Grinnell BW, Hermann RB, Yan SB. Human protein C inhibits selectin mediated cell adhesion: Role of unique fucosylated oligosaccharide. Glycobiology 1994;4:221225.
  • 32
    Grey ST, Tsuchida A, Hau H, et al. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 1994;153:36643672.
  • 33
    Bernard GR, Vincent JL, Laterre PF. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699709.